UCB

Allée de la Recherche, 60
1070 BRUXELLES
Belgium

[email protected] +32 473 95 52 98 www.ucb.com

Follow them

Type
- Company
Core business
- Production
- R&D
Technology
- Cell therapy
- Gene therapy
Therapeutic area

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, focusing on innovative treatments for severe diseases in immunology and neurology.

Related projects

Projects

NEMO

GTRP-DIAT

Targetum

All member's projects

Related news

News

U.S. FDA approves KYGEVVI[™] (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

All member's news

Related jobs

Jobs

Patient Supply Digital Change Lead

Braine L'alleud | Fixed contract - Full time | Finance

All member's jobs